论文部分内容阅读
胚胎抗原(CEA)是应用最为广泛的结直肠癌肿瘤标志物,为了探讨CEA下降比率在结直肠癌新辅助放化疗中的作用,Huang CS等研究了284例接受新辅助放化疗后行根治性手术的患者,研究中根据新辅助放化疗前血清CEA水平分为3组:组1为CEA<5μg/L,组2为新辅助放化疗前血清CEA≥5μg/L且CEA下降比率≥50%,组3为新辅助放化疗前血清CEA≥5μg/L且CEA下降比率<50%。结果显示,5年无病生存率组1和组2比较,差异无统计学意义(71.8%比69.4%,P0053 4951 P0052 P005
Embryonic antigen (CEA) is the most widely used tumor marker of colorectal cancer. To investigate the role of CEA decline in neoadjuvant chemoradiation of colorectal cancer, Huang CS et al studied 284 patients who underwent neoadjuvant chemoradiotherapy after radical chemotherapy According to the level of serum CEA before neoadjuvant chemoradiation and chemotherapy, the patients were divided into 3 groups: CEA <5μg / L in group 1, CEA≥5μg / L before neoadjuvant chemoradiation and chemotherapy, and the reduction rate of CEA≥50% , Group 3 neoadjuvant chemoradiation serum CEA ≥ 5μg / L and CEA decline rate <50%. The results showed that there was no significant difference in the 5-year disease-free survival rate between group 1 and group 2 (71.8% vs. 69.4%, P0053 4951 P0052 P005